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Cell proliferationANKHD1 is highly expressed in human acute leukemia cells and potentially regulates multiple cellular functions
through its ankyrin-repeat domains. In order to identify interaction partners of the ANKHD1 protein and its role
in leukemia cells, we performed a yeast two-hybrid system screen and identiﬁed SIVA, a cellular protein known
to be involved in proapoptotic signaling pathways. The interaction betweenANKHD1 and SIVAwas conﬁrmed by
co-imunoprecipitation assays. Using human leukemia cell models and lentivirus-mediated shRNA approaches,
we showed that ANKHD1 and SIVA proteins have opposing effects. While it is known that SIVA silencing pro-
motes Stathmin 1 activation, increased cell migration and xenograft tumor growth, we showed that ANKHD1 si-
lencing leads to Stathmin 1 inactivation, reduced cell migration and xenograft tumor growth, likely through the
inhibition of SIVA/Stathmin 1 association. In addition, we observed that ANKHD1 knockdown decreases cell pro-
liferation, without modulating apoptosis of leukemia cells, while SIVA has a proapoptotic function in U937 cells,
but does not modulate proliferation in vitro. Results indicate that ANKHD1 binds to SIVA and has an important
role in inducing leukemia cell proliferation andmigration via the Stathmin 1 pathway. ANKHD1may be an onco-
gene and participate in the leukemia cell phenotype.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Acute leukemia represents a group of clonal hematopoietic stem cell
disorders characterized by alterations in the essential pathways of cell
physiology including apoptosis, proliferation and genome instability,
which may be caused by deregulation of signal transduction pathways
that involve the coordinated action of many different proteins [1,2].
The identiﬁcation of overactive proteins in leukemia cells, compared
to normal hematopoietic cells, as well as the understanding of the mo-
lecular and cellular basis of the disease may provide new therapeutic
opportunities.therapy Center, University of
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aulo at Ribeirão Preto MedicalAnkyrin Repeat and KHDomain Containing 1 protein, ANKHD1, was
initially identiﬁed, in humans, as a cytoplasmic protein that is highly
expressed in acute leukemia cells, compared to normal hematopoietic
cells [3]; however functional studies of ANKHD1 in leukemia cells are
still lacking. A hallmark of ANKHD1 is the presence of 20 ankyrin-
repeat domains. Each repeat consists of about 33 amino acids that fold
into a β-turn, followed by two antiparallel α-helices, which function
to mediate protein–protein interactions [4]. Ankyrin-repeat proteins
are found in all species and are fundamental to biological processes, in-
cluding cell cycle control, transcriptional regulation, differentiation, ap-
optosis, cytoskeletal organization, and may be involved in the
development of neoplasia [5]. In solid tumors, ANKHD1 has been
found to be associated with YAP1 and negatively impacts the prognosis
of patients with breast cancer [6]. However, YAP1 is not expressed in
leukemia cells [7,8], and the role of ANKHD1 in leukemia remains
unknown.
Thepresence ofmultiple ankyrin repeats suggests a role for ANKHD1
as a scaffolding protein, bringing together a number of signaling mole-
cules. To obtain new insight into the signaling properties of ANKHD1
and to identify novel interacting proteins that mediate its functions in
584 J.A. Machado-Neto et al. / Biochimica et Biophysica Acta 1853 (2015) 583–593leukemia cells, we used the ankyrin-repeat domain of ANKHD1 as bait
in a yeast two-hybrid (Y2H) assay and identiﬁed the proapoptotic pro-
tein, SIVA.The SIVA gene is a transcriptional target of p53 that was initially de-
scribed as a proapoptotic protein acting in both extrinsic and intrinsic
apoptotic pathways [9,10]. In acute lymphoid leukemia cell lines, both
Fig. 2. Efﬁcient ANKHD1 and SIVA silencing in U937 and Jurkat leukemia cell lines. U937 or Jurkat leukemia cells were transduced with lentivirus-mediated shRNA control (shControl),
lentivirus-mediated shRNA targeting ANKHD1 (shANKHD1) or SIVA (shSIVA). ANKHD1 mRNA (A) and protein (B) expression in shANKHD1 cells relative to the shControl cells. SIVA1
mRNA (C) and protein (D) expression in shSIVA cells relative to the shControl cells. The antibodies used for immunoblotting (IB) are indicated. Images are representative of at least
three independent lentivirus-mediated shRNA transduction experiments; Western blot analyses were performed in duplicate for each lentivirus-mediated shRNA transduction.
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ptotic pathway induced through the CD27 antigen [11]. SIVA1 binds to
BCL-XL, BCL2 and XIAP, negatively regulates the anti-apoptotic NFκB
and positively regulates the proapoptotic JNK functions [12–14]. In
solid tumors, SIVA1 binds to Stathmin 1 and is essential to the Stathmin
1/CaMKII interaction and CaMKII phosphorylates Stathmin 1 at serine
16, decreasing Stathmin 1's activity [15]. Stathmin 1 phosphorylation
at speciﬁc serine sites reduces its afﬁnity with alpha/beta-tubulin and
leads to microtubule stability [16], which can be evidenced by alpha-
tubulin acetylation [15].
Thereby, Stathmin 1 regulates microtubules dynamics by promoting
depolymerization of microtubule or preventing polymerization of tubu-
lin heterodimers, and is important for accurate chromosome segregation,
cell division, proliferation and migration [17]. We, thus, hypothesized
that ANKHD1 could be involved in leukemogenesis through its interac-
tion with SIVA.
2. Materials and methods
2.1. Quantitative polymerase chain reaction
Quantitative PCR (qPCR) was performedwith an ABI 7500 Sequence
Detector System (Applied Biosystems, Foster City, CA, USA) with specif-
ic primers for ANKHD1 (FW: 5′-CCTGCTTGGAACCCTATGATAAA-3′; RV:
5′-CGTGCCAGGCCAAATCTG-3′), SIVA1 (FW: 5′-TCTTCGAGAAGACCAA
GCG-3′; RV: 5′-TGCCCAAGGCTCCTGATC-3′) and HPRT (FW: 5′-GAACFig. 1. ANKHD1 is a binding partner of SIVA. (A) Schematic representation of the primary prot
screen;ANKRD, ankyrin repeat domain; KH, K homology domain; SAH,Amphipathic helical regi
of the amino acid sequence obtained from Y2H clone and from the SIVA1 and SIVA2 proteinswe
regions containing similarity are indicated in red. (B) Immunoprecipitation (IP) and immunob
SIVA2 with speciﬁc antibodies. Western blots and IP images are representative of at least two
(IB) of U937 cells with anti-ANKHD1 or anti-SIVA antibody. Total protein extract (input) and is
munoblotting are illustrated. (D) Confocal analysis of U937 and Jurkat cells displaying SIVA (
Colocalization analysiswas performedwith the “colocalization ﬁnder” plugin of ImageJ NIH soft
in white. The correlation coefﬁcient (r) values are indicated. Confocal analyses of cells were peGTCTTGCTCGAGATGTG-3′; RV: 5′-TCCAGCAGGTCAGCAAAGAAT-3′).
Relative gene expression was calculated using the equation 2−ΔΔCT
[18]. A negative ‘No Template Control’ was included for each primer
pair. The dissociation protocol was performed at the end of each run
to check for non-speciﬁc ampliﬁcation. All samples were tested in
triplicate.
2.2. Plasmids
The plasmids pEGFPC1, pEGFPC1-SIVA1, and pEGFPC1-SIVA2 were
kindly provided by Dr. Serge Benichou (Institut Cochin, Université
Paris Descartes, Paris, France) [19]. The pcDNA3-3HA-ANKHD1 plasmid
was kindly provided by Dr. Nahum Sonenberg (Biochemistry Dept., Mc-
Gill University, Montreal, Canada) [20].
2.3. Yeast two-hybrid assay
The Matchmaker Two-Hybrid System 3 (Clontech, Palo Alto, CA,
USA) was used to screen a human bone marrow cDNA library (in
pACT2) with pGBKT7-ANKHD1 (aa 1130–1243) as the bait. The choice
of the ANKHD1 bait prioritized the inclusion of sequences encoding an-
kyrin domain, and the exclusion of aminoacid regions with very nega-
tive charges to avoid self-activation of the bait [21,22]. Peptide
sequence analysis was performed using Gene Runner (http://www.
generunner.com). Co-transformation of the bait and prey plasmids
was performed according to the lithium-acetate transformationein structures, the ANKHD1-bait and SIVA-preys identiﬁed in our yeast two-hybrid (Y2H)
on;DDRH, death domain homology region; andZF, zincﬁnger-like domain. The alignments
re performed byMultalin software (http://bioinfo.genopole-toulouse.prd.fr/multalin); the
lotting (IB) of HEK293T lysates overexpressing HA-ANKHD1 and GFP, GFP-SIVA1 or GFP-
independent co-transfections assays. (C) Immunoprecipitation (IP) and immunoblotting
otype IgG antibody were used as controls. Two replicates of immunoprecipitation and im-
green), ANKHD1 (red) and DAPI (blue) staining; MERGE shows the overlapped images.
ware and showsmerged images of ANKHD1and SIVA; the colocalized points are visualized
rformed in at least three independent experiments.
Fig. 3.ANKHD1 and SIVA silencing have opposing effects on leukemia cell migration and Stathmin 1 activation. Transwellmigration assay of U937 and Jurkat leukemia cells submitted to shControl, shANKHD1 (A) or shSIVA (B) in the presence of 0.5%
BSA, 10% FBS or 200 ng/mL CXCL12, the results aremean± SD of at least three independent experiments; *p b 0.05, **p b 0.01; Student t test.Western blot analysis for Stathmin 1 phosphorylation and alpha-tubulin acetylation in U937 and Jurkat cells
transducedwith shControl, shANKHD1 (C) or shSIVA (D). Immunoprecipitation (IP) of SIVA and immunoblotting (IB)with anti-Stathmin 1 in shControl and shANKHD1 cells; total protein extract (input)was used as control (E).Western blot analysis
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clones were conﬁrmed by an X-gal ﬁlter assay [23] and the inserts
were identiﬁed by PCR and sequencing. Two independent co-
transformations of the bait and prey plasmids were performed.
2.4. Lentiviral vectors
The preparations of lentiviral vectors expressing the human
short hairpin RNA (shRNA) target ANKHD1 (shANKHD1) or LacZ
(shControl) were performed using the BLOCK-It Lentiviral RNAi
Expression System (Invitrogen; Carlsband, CA, USA), as previously
described [24]. Lentivirus-mediated shRNA targeting SIVA (shSIVA;
sc-37385-V), Stathmin 1 (shSTMN1; sc-36127-V) or shRNA nonspe-
ciﬁc control (shControl; sc-108080) were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA), following the manufacturer's
instruction.
2.5. Cell culture, transfection and transduction
U937, Jurkat and HEK293T cells were obtained from ATCC, Philadel-
phia, PA, USA. Cells were cultured in appropriate medium containing
10% fetal bovine serum (FBS) and glutamine with penicillin/streptomy-
cin and amphotericin B, andmaintained at 37 °C, 5% CO2. HEK293T cells
were transiently co-transfected with 8 μg of the DNA plasmid of HA-
ANKHD1, and GFP, GFP-SIVA1 or GFP-SIVA2 using a calcium phosphate
procedure. After 24 h, the cells were harvested and total extract was
prepared and submitted to immunoprecipitation and Western blot.
U937 and Jurkat cells were transduced with lentivirus-mediated
shRNA control, lentivirus-mediated shRNA targeting ANKHD1 or SIVA;
named shControl, shANKHD1 and shSIVA cells, respectively. In addition,
for the xenograft model of tumorigenesis studies, U937 cells were also
transduced with both shANKHD1 and shSIVA. Brieﬂy, 2 × 105 cells
were transduced with lentivirus by spinoculation at a multiplicity of in-
fection of equal to 3 and selected by blasticidin (10 μg/mL) for the
Invitrogen system and/or by puromycin (1 μg/mL) for the Santa Cruz
Biotechnology system.
2.6. Western blot analysis and immunoprecipitation
Equal amounts of protein were used for total extracts or for immu-
noprecipitation with speciﬁc antibodies followed by SDS–PAGE and
Western blot analysis with the indicated antibodies and the ECL West-
ern Blot Analysis System (Amersham Pharmacia Biotech, UK). Antibod-
ies against ANKHD1 (sc-160960), SIVA (sc-7436), GFP (sc-8334), HA
(sc-805), p-Stathmin 1 (sc-12948-R), Stathmin 1 (sc-55531), alpha tu-
bulin (sc-5286), BCL-XL (sc-8392), BAX (sc-20067), BCL2 (sc-492),
YAP1 (sc-101199), SHP2 (sc-280), JAK2 (sc-294), STAT3 (sc-7179),
STAT5 (sc-835) and Actin (sc-1616) were from Santa Cruz Biotechnolo-
gy. Antibodies against p-JNK (44690G), JNK (446826), p-ERK1/2
(44654G) and ERK1/2 (700012) were from Invitrogen, the antibodies
against p-YAP1 (#4911S), p-SHP2 (#3751S), p-JAK2 (#3774S), p-
STAT3 (#9131S), and p-STAT5 (#9359S) were from Cell Signaling Tech-
nology (Danvers,MA, USA), the antibody against ANKHD1 (A303-306A)
was fromBethyl Laboratories (Montgomery, TX, USA), and the antibody
against acetyl-alpha tubulin (ab24610) was from Abcam (Cambridge,
MA, USA).
2.7. Confocal immunoﬂuorescence microscopy
Confocal imaging was carried out using primary antibodies against
ANKHD1 or SIVA (diluted 1:100), as previously described [3]. The
“colocalization ﬁnder” plugin of Image J quantiﬁcation software (U.S.
National Institutes of Health, Bethesda,MD, USA) was used for the anal-
ysis of ANKHD1 and SIVA colocalization.2.8. Migration assays
Migration assays were performed in duplicate using 8 μm pore size
transwells (Corning Costar; Cambridge, MA, USA). The transwells
were initially washed twice with PBS and blocked for 1 h at 37 °C with
0.5% BSA in RPMI and the lower compartment was ﬁlled with 500 μL
0.5% RPMI containing 10% FBS, 0.5% BSA plus 200 ng/mL CXCL12 or
0.5% BSA. Cells (1 × 105 in 100 μL) were applied to the upper compart-
ment and allowed to migrate for 24 h. The migrated cells were counted
and expressed as a percentage of the input.
2.9. Methylthiazoletetrazolium (MTT) assay
Cell growth/viability was measured by MTT assay as previous de-
scribed [24]. Cells were serum-starved in 0.5% FBS for 12 h. A total of
5 × 104 cells per well were then plated in a 96-well plate in RPMI 10%
FBS. In brief, 10 μL of a 5 mg/mL solution of MTT was added to the
wells and incubated at 37 °C for 4 h. The reaction was stopped using
100 μL 0.1 N HCl in anhydrous isopropanol. Cell growth/viability was
evaluated bymeasuring the absorbance at 570 nm, using an automated
plate reader. All conditions were tested in six replicates.
2.10. Colony formation assay
Colony formation was carried out in semisolid methyl cellulose
medium. Cells (1 × 103 cell/mL) were seeded in MethoCult 4230
(StemCell Technologies Inc.; Vancouver, BC, Canada). Colonies
were detected after 10 days of culture by adding 1 mg/mL of MTT re-
agent and scored by Image J quantiﬁcation software (U.S. National
Institutes of Health).
2.11. Apoptosis assays
For apoptosis evaluation, cells were seeded on 12-well plates and
evaluated at 0, 3, 6 and 12 h after UV exposition (40 J/m2). ShControl
or shSIVA U937 cells were also treated with daunorubicin (1 and
2 μM; Actavis Italy S.p.A, Milan, Italy) for 48 h. Cells were then washed
twice with ice cold PBS and resuspended in binding buffer containing
1 μg/mL PI and 1 μg/mL APC or FITC labeled Annexin-V. All specimens
were analyzed on a FACSCalibur after incubation for 15 min at room
temperature in a light-protected area. Ten thousand events were ac-
quired for each sample.
2.12. Xenograft model of tumorigenesis in NOD/SCID mice
Mice were provided by the University of Campinas Central Breed-
ing Center (Campinas, SP, Brazil). Experimental groups consisted of
6–8 week-old female non-obese diabetic/severe combined immuno-
deﬁciency (NOD/SCID) mice, injected with 1 × 107 U937 cells
(resuspended in 100 μL of PBS) that were either shControl,
shANKHD1, shSIVA, or both shANKHD1 and shSIVA transduced.
Cells were implanted into the dorsal sub cutis of mice. After
12 days, tumors were excised, measured and weighed. Tumor mea-
surements were converted to tumor volume (V) using the formula
(V=W2 × L × 0.52), whereW and L are the smaller and larger diam-
eters, respectively [25]. All experiments were approved by the Ethics
Committee of the University of Campinas.
2.13. Statistical analysis
Statistical analyses were performed using GraphPad Instat 5
(GraphPad Software, Inc., San. Diego, CA, USA). For comparisons,
Student's t-test or Mann–Whitney test were used, as appropriate. A p-
value b0.05 was considered as statistically signiﬁcant.
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3.1. ANKHD1 binds to SIVA
In order to identify interaction partners of the ANKHD1 protein,
we performed a Y2H screen of a human bone marrow cDNA library
using a fragment of ANKHD1 containing an ankyrin-repeat domain
and encompassing the region comprised between aa 1130 and 1243
as a bait. Among different clones, we identiﬁed one coding for the C-
terminal of both SIVA isoforms (Fig. 1A). The association of ANKHD1
with SIVA1 and SIVA2 was conﬁrmed in immunoprecipitation experi-
ments using HEK293T cells co-expressing HA-ANKHD1 in combination
with GFP-SIVA1 or GFP-SIVA2 proteins. Protein extracts were immuno-
precipitated with antibody against GFP and immunoblotted with anti-
body against HA. HEK293T cells co-expressing HA-ANKHD1 and GFP
were used as a negative control (Fig. 1B). The interaction between en-
dogenous proteins was veriﬁed by immunoprecipitation and immuno-
blotting of the human leukemia cell line U937 with ANKHD1 and SIVA
antibodies (Fig. 1C). Finally, confocal microscopy analysis revealed co-
localization of the endogenous ANKHD1 and SIVA proteins in the cyto-
plasm of U937 and Jurkat human leukemia cells (Fig. 1D).
3.2. ANKHD1 silencing inhibits cellmigration and Stathmin 1 activity in leu-
kemia cells
U937 and Jurkat cells were stably transduced with lentivirus-
mediated shRNA targeting ANKHD1 (shANKHD1), SIVA (shSIVA) or an
appropriate control (shControl), and efﬁciently silenced for ANKHD1
and SIVA (Fig. 2).
Transwellmigration assay revealed that ANKHD1 silencing decreased
themigration capacity of U937 and Jurkat cells upon FBS or CXCL12 stim-
ulation (p b 0.05; Fig. 3A). In contrast, a signiﬁcant enhancement of mi-
gration was observed in shSIVA cells, when compared to shControl
cells in U937 and Jurkat cells (p b 0.05; Fig. 3B).
ANKHD1knockdown resulted in Stathmin 1 inactivation, as revealed
by phosphorylation, and alpha-tubulin acetylation (Fig. 3C), indicating a
stabilization of tubulin microtubules in agreement with the lower mi-
gration capacity of shANKHD1-transduced cells. In contrast, SIVA
knockdown resulted in Stathmin 1 activation, as reﬂected by the de-
crease in phosphorylation on Ser16, and alpha-tubulin deacetylation
compared to shControl cells (Fig. 3D).
We then investigated whether ANKHD1 modulates the SIVA/
Stathmin 1 interaction. In U937 leukemia cells, ANKHD1 silencing result-
ed in increased SIVA/Stathmin 1 association (Fig. 3E), indicating that the
presence of ANKHD1 inhibits the SIVA/Stathmin 1 interaction and con-
tributes to Stathmin 1 activation. Notably, in leukemia cells, we found
that ANKHD1 silencing presented a similar phenotype as previously de-
scribed for Stathmin 1 silencing with regard to cell proliferation,
clonogenicity, apoptosis [26–28] and microtubule dynamics (Fig. 3F).
3.3. ANKHD1 does not modulate UV-induced apoptosis in leukemia cells
Using a UV radiation-induced apoptosis model, ANKHD1 silencing did
notmodulate apoptosis inU937 and Jurkat leukemia cells, nor the expres-
sion of apoptosis-related proteins, BCL-XL, BAX, BCL2 and p-JNK (Fig. 4). A
signiﬁcant reduction in the apoptotic response was observed in shSIVA
following UV radiation exposure, when compared to shControl cells inFig. 4.ANKHD1does notmodulateUV-induced apoptosis in leukemia cells. Apoptosiswas dete
B) and shSIVA cells (C–D) after UV radiation exposition (40 J/m2) using Annexin-V/PI stainingm
viable (Annexin-V−/PI−), apoptotic (Annexin-V+/PI−) or necrotic cells (Annexin-V+/PI+
ments; *p b 0.05, **p b 0.01, ***p b 0.001; Student t test. Western blot analysis for the express
shANKHD1 (E) and shSIVA cells (F); membranes were reprobedwith the antibody for detection
System. The leukemia cell lines used are indicated. Western blot images are representative of aU937 cells (p b 0.05), but not in Jurkat cells. Similar results were observed
in shControl and shSIVA U937 cells following daunorubicin treatment
(Supplementary Fig. 1). In addition, in U937 cells, knockdown of SIVA re-
sulted in thedownregulation of JNKphosphorylation andBAXexpression,
and upregulation of BCL-XL expression (Fig. 4), indicating a lower sensi-
bility to apoptosis, but no changes in BCL2 protein levels were observed.
3.4. ANKHD1 modulates leukemia cell growth and clonogenicity
Stathmin 1 regulates microtubule dynamics, which is an impor-
tant mechanism involved in cell proliferation. We investigated the
role of ANKHD1 and SIVA in cell growth and clonogenicity in U937
and Jurkat leukemia cells in vitro. Cell growth and clonal growth
were signiﬁcantly reduced in shANKHD1 cells, when compared
with shControl (p b 0.05). SIVA silencing did not modulate cell
growth and clonogenicity (Fig. 5). These data indicate that
ANKHD1 has an important role in the cell growth of leukemia cells
in vitro, but the effect of SIVA on cell proliferation remains unclear
and may vary in different cell types [29].
3.5. ANKHD1 and SIVA have opposing effects on tumor growth of leukemia
cells in vivo
Xenograft tumor formation is a multistep process that involves apo-
ptosis and cell growth. Based on our ﬁndings regarding the role of
ANKHD1 and SIVA in leukemia cells in in vitro assays, we analyzed the
effects of SIVA and ANKHD1 silencing on tumor formation of leukemia
cells in vivo.
U937 cells stably transduced with shANKHD1, shSIVA, both
shANKHD1 and shSIVA, or shControl, were implanted into female NOD/
SCID mice by subcutaneous injection, and tumors were allowed to grow
for 12 days. ANKHD1 and SIVA had opposing effects on tumor growth
in vivo. While ANKHD1 silencing resulted in a signiﬁcant reduction of
tumor growth of leukemia cells in vivo (p b 0.05, Fig. 6A), SIVA knock-
down potentiated tumor growth of leukemia cells (p b 0.05; Fig. 6B). In-
terestingly, the respective effects of ANKHD1 and SIVA on the tumor
growth of leukemia cells in vivo were abrogated when both proteins
were depleted simultaneously (Fig. 6C), indicating that both proteins
may be involved in the same signaling pathway; in addition, the pheno-
type effect of ANKHD1 silencing depends on the presence of SIVA.
3.6. ANKHD1 silencing does not modulate the Hippo, SHP2 and JAK2/STAT
signaling pathways in leukemia cells
Since previous studies have reported that ANKHD1 and/or its
ortholog protein mask (multiple ankyrin repeats single KH domain) is
involved in YAP1 (ortholog of Yorkie; yki) [6,24,30,31], SHP2 (ortholog
of Corkscrew; csw) [3,32] and JAK2 (ortholog of Hopscotch; hop) [33]
signaling, we veriﬁed the activation of these signaling pathways in leu-
kemia cells submitted to ANKHD1 silencing. However, in U937 and
Jurkat cells, we found that these signals are not activated, and not mod-
ulated by ANKHD1 silencing (Fig. 7). In agreement with recent studies
reported by our group and others, YAP1 is expressed at very low or un-
detectable levels in leukemia cells [7,8], Taken together, we conclude
that the effects of ANKHD1 silencing on leukemia cell growth and
clonogenicity are not associated with Hippo, SHP2 or JAK2/STAT signal-
ing pathways.cted byﬂowcytometry inU937 and Jurkat cells transducedwith shControl, shANKHD1 (A–
ethod and a representative dot plot is illustrated. Bars indicate the relative number of (%)
plus Annexin-V−/PI+); and represents the mean of at least three independent experi-
ion of BCL-XL, BAX, BCL2 and phospho-JNK (p-JNK) in total cell extracts from shControl,
of the respective total protein or actin, and developedwith the ECLWestern Blot Analysis
t least three replicates.
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Fig. 5.ANKHD1, but not SIVA,modulates leukemia cell growth in vitro. Cell growthwas determinedbyMTT assay at 48 h of incubation of shANKHD1 (A) or shSIVA cells (B) and normalized
by the corresponding shControl cells. Results are shown as mean ± SD of six replicates and are representative of at least three independent experiments; *p b 0.05, **p b 0.01;Mann–
Whitney test. Colonies containing viable cells were detected byMTT after 8 days of culture of shANKHD1 (C) or shSIVA cells (D) and normalized by the corresponding shControl cells. Re-
sults are shown as mean ± SD of at least three independent experiments performed in triplicate; **p b 0.01, ***p b 0.001; Student t test.
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To explore the possibility that theANKHD1protein plays a role in leu-
kemia processes, our aim was to identify cellular ANKHD1-interacting
proteins that could drive our investigation towards a speciﬁc signaling
pathway. Using an ankyrin-repeat domain of ANKHD1, we were able to
identify SIVA as a binding partner of ANKHD1. This ﬁnding prompted
us to evaluate the role of ANKHD1 in important cellular processes
known to be modulated by SIVA; migration, apoptosis, and proliferation
[34]. Ourﬁrst hypothesiswas that ANKHD1 couldmodulate apoptosis, as
SIVA has been well established as a proapoptotic protein [34,35].
We conﬁrmed that SIVA silencing reduced irradiation-induced apoptosis
in U937 myeloid leukemia cells, downregulated the proapoptotic
proteins p-JNK and BAX, and upregulated the anti-apoptotic protein
BCL-XL, as previously described in other cancer cell lines [12–14,36,37].
However, ANKHD1 silencing did not change the percentage of apoptotic
cells nor the expression of apoptotic proteins. Our data are still limited to
enable us to justify why ANKHD1 and SIVA interact; however, results
suggest that only SIVA plays a role in the apoptotic process in vitro. It
is well recognized that leukemia cells have complex signaling path-
ways [2] and different partners of each protein may deﬁne speciﬁc
functions.
We then investigated a possible role for ANKHD1 in another signal-
ing pathway known to be modulated by SIVA. It has recently been re-
ported that SIVA1 suppresses the epithelial–mesenchymal transition
andmetastasis of solid tumor cells by inhibiting Stathmin 1 and stabiliz-
ingmicrotubules [15]. Stathmin 1 is a microtubule destabilizing protein
with a key role in cell cycle progression and cell migration that is up-
regulated in several cancers, including acute leukemia [16,38–40].
Therefore, therapeutic modalities designed to interfere with Stathmin
1 expression to inhibit cell proliferation, angiogenesis and cellmigration
are of interest in several types of cancer [16,41–43], and a betterunderstanding of the complex signaling network of the Stathmin 1
pathway in leukemia could add new insights in this ﬁeld.
We conﬁrmed the inhibitory effect of SIVA on Stathmin 1 activation
with a consequently increased cell migration of leukemia cells [15]. In-
terestingly, ANKHD1 had an opposite effect on Stathmin 1 and migra-
tion, since ANKHD1 silencing resulted in Stathmin 1 inactivation,
alpha-tubulin acetylation and reduced cell migration. Li et al. reported
that SIVA overexpression resulted in a similar phenotype to that ob-
served by us following ANKHD1 silencing [15]. These opposing effects
suggest that ANKHD1 binds to SIVA and inhibits its function in the
Stathmin 1 pathway. These data are supported by our ﬁndings that, in
U937 leukemia cells, ANKHD1 silencing enhances the SIVA/Stathmin 1
interaction and that the phenotype effect of ANKHD1 silencing on
in vivo tumor growth depends on the presence of SIVA.
Although we observed an opposite effect of ANKHD1 and SIVA on
migration, Stathmin 1 pathway and xenograft tumor growth, we were
not able to document a potential role of SIVA on leukemia cell prolifer-
ation in vitro. The effect of Stathmin 1 on proliferation has been well de-
ﬁned and low levels of Stathmin 1 stabilize the mitotic spindle, prevent
mitosis and inhibit proliferation in tumors and leukemia cells [27,41,
43]. Accordingly, we found that ANKHD1 silencing resulted in Stathmin
1 inhibition and decreased in vitro leukemia cell proliferation and xeno-
graft tumor growth. In Drosophila, recent studies also found that the
orthologous protein of ANKHD1, mask, is essential for cell proliferation
and tissue growth [6,30], corroborating our ﬁndings in human cells.
SIVA silencing resulted in increased in vivo tumor growth, but did not
modulate in vitro proliferation and colony formation. Two major points
need to be discussed here: i) First, why were the opposing effects of
ANKHD1 and SIVA silencing observed only in vivo, but not in vitro as-
says? ii) Secondly, how do we justify our results regarding the effect
of SIVA silencing on proliferation, compared to the work of Du et al.
[29]?
Fig. 6. ANKHD1 and SIVA have opposing effects on xenograft tumor formation in NOD/SCID mice. Tumor measurement (volume and weight) at 12 days after subcutaneous injection of
shControl, shANKHD1 (A), shSIVA (B), or both shANKHD1 and shSIVA cells (C) in female NOD/SCID mice. Tumor volume (V) was calculated using the formula (V =W2 × L × 0.52),
where W and L are the smaller and larger diameters, respectively. Number of animals is indicated; *p b 0.05, **p b 0.01; Mann–Whitney test. (D) Potential model for the role of
ANKHD1 and SIVA in leukemia cells; 1: SIVA is an adaptor protein that promotes Stathmin 1 phosphorylation and inactivation, and negatively regulates leukemia cell migration; 2:
ANKHD1 binds to SIVA and leads to Stathmin 1 activation, tubulin depolymerization, increased cell migration and proliferation; 3: SIVA induces apoptosis by upregulation of the
proapoptotic proteins BAX and p-JNK and downregulation of the anti-apoptotic protein BCL-XL. Abbreviations: Ac: acetylation; P: phosphorylation. Figure was produced using Servier
Medical Art (http://www.servier.com/Powerpoint-image-bank).
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icant reduction of in vitro and in vivo proliferation in cancer cells wild-
type for TP53, colon carcinoma (HCT116) and osteosarcoma (U2OS)
cells, but not in TP53 null cancer cells [29]. In AML, TP53mutation is fre-
quent and it is associated with worse prognosis and survival [44]. All
leukemia cell lines used in our studies present a TP53mutation (inactive
form) [45,46]. Thus, as indicated by Du et al., the effects of SIVA on pro-
liferation and tumor growth vary according to the mutation status of
TP53. In the leukemia cells lacking the wild-type TP53, the effect of
SIVA silencing on tumor growth may be related to increased resistance
to apoptosis, or also due to Stathmin 1 activation.
In conclusion, we observed that ANKHD1 binds to SIVA and leads to
Stathmin 1 activation, tubulin depolymerization, increased cell migra-
tion and proliferation (Fig. 6D), possibly due to SIVA inhibition.
ANKHD1 may be an oncogene and participate in the leukemia cell
phenotype.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.12.012.
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